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Objectives: Asthma is a common disease in most countries. The objective of this study
was to estimate the societal costs for subjects with asthma.
Methods: Telephone interviews regarding resource utilization were made in a represen-
tative sample of 115 randomly selected subjects with asthma derived from a large
population study of obstructive airway diseases. Direct and indirect costs were measured,
and the costs were also transformed with the estimated prevalence of asthma in Sweden.
Results: Average annual costs were SEK 15 919 (USD 1592; EUR 1768) per subject with
asthma in the ages between 25 and 56 years. The direct and indirect costs were SEK 4931
(31.0%) and SEK 10 988 (69.0%), respectively, and were highly dependent of age and
disease severity. Assuming that the prevalence is representative for Sweden as a whole,
the asthmatics would amount to 226 000 in the ages between 25 and 56 years,
corresponding to an overall prevalence in Sweden of 6–7%. The total costs of asthma for
the society amounted thus to SEK 3.7 billion in these ages.
Conclusions: The total costs of asthma for the society could be estimated at 3.7 billion
SEK in the age range of 25–56 years, and thus approximately twice as high in the whole
population of Sweden. The costs were strongly dependent on disease severity and
increasing age.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Asthma is a major health problem in society. The disease
seriously affects children and adults, and the prevalence hasElsevier Ltd. All rights reserved.
776841.
holmsund.nu (S.-A. Jansson).increased considerably over the past five decades.1,2 Studies
in both Europe and USA show a similar trend.3–5 The increase
has also been demonstrated in Sweden.6 The prevalence of
asthma in 1990s was about 5–9% in the population in
northern and western Europe with variations between
countries and regions within countries.7
In particular, for diseases with a high prevalence, it is
important to get knowledge of the economic implications of
ARTICLE IN PRESS
Table 1 Number of participants by age, gender, and
severity of asthma.
Severity of asthma Age (years) Total (M/F)
25–26 40–41 55–56
Persistent 17 16 29 62 (26/36)
Mild intermittent 33 15 5 53 (21/32)
Total 50 31 34 115 (47/68)
S.-A. Jansson et al.2264the diseases. Studies about costs of asthma have therefore
been performed in many countries, both in Europe and in
other parts of the world.8 Most of them have been register
studies and studies of health statistics.9–15 However, there is
a lack of studies using data of representative samples of
asthmatics derived from studies of the general population
when estimating the burden of illness of asthma. In a Dutch
study using register data based on identified cases, the
direct costs for asthma and chronic obstructive pulmonary
disease (COPD) were estimated at 1.3% of the Dutch health
care budget in 1993.9 A similar proportion was found in a
study performed in the USA.11
Cost-of-illness-studies examine the economic impact of
illness in the society, which usually means that both direct
and indirect costs are included.16 Direct costs refer to
medical care including prevention, diagnostics, treatment,
rehabilitation, etc. Indirect costs consist of loss of produc-
tivity, which has an effect on society due to days off from
work and to early retirement caused by the disease. When
measuring cost of illness, two different approaches can be
used, the prevalence approach and the incidence ap-
proach.17 The prevalence approach estimates costs of a
disease mostly during a 1-year period, while the incidence
approach measures costs in a lifetime perspective.
The aim of this study was to estimate the societal burden
of illness for adult asthma for the Swedish society and to
evaluate the costs according to age and severity of asthma.
The study also aimed to identify the key cost drivers of
asthma.
Material and methods
Data were collected by telephone interviews of randomly
selected subjects with asthma derived from a population
study in northern Sweden in 1996. The Ethics Committee at
the University Hospital of northern Sweden in Umea
approved the study.
Study population
The study sample was generated from large-scale population
studies of the epidemiology of obstructive airways diseases
and type-1 allergy in northern Sweden, the Obstructive Lung
Disease in northern Sweden (OLIN) Studies.18–20 The sample
in the current study was derived from one of the OLIN-
cohorts. The cohort consisted of a representative sample of
individuals born in 1940–41, 1955–56 and 1970–71,21,22 and
they were 25–26, 40–41, and 55–56 years of age at the time
of the interviews. The study sample consisted of subjects
who had either a physician-diagnosed (‘‘Have you been
diagnosed as having asthma by a physician?’’) or a self-
reported asthma (‘‘Have you ever had asthma?’’), and in
addition used asthma medications, and had symptoms
common in asthma such as attacks of shortness of breath
or recurrent wheeze.
In total, 352 subjects with current asthma were identi-
fied, of whom 86.9% had reported a physician-diagnosis.
A random sample was drawn from each age group in order to
obtain a study sample of sufficient size to allow measures of
total societal costs, and thus 129 asthmatics were invited,
and 115 (59% women) participated. Of them, 46% had mildintermittent asthma, and 54% had persistent asthma.
Persistent versus mild intermittent asthma was classified
based on use or not use of inhaled cortico-steroids, a
classification fairly in accordance with the GINA guide-
lines.23 Women were more frequent in both severity grades.
The demographic and disease-specific characteristics of the
study sample are shown in Table 1.
Methods
Before the telephone interviews took place, a letter was
sent to the patients with information about the study.
A specially designed and pilot-tested questionnaire was
used to record asthma-specific resource use. The interviews
retrospectively covered resource use for a period of
1 year. The questions asked included number of visits to
the health-care sector, number of days in hospital, use of
medication, number of days off work, early retirement,
change of habitation, change of profession, and need
for home equipments due to asthma. The interviews
lasted 15–45min each and were carried out by the same
person (SAJ).
Costs
Both direct and indirect costs were recorded. The direct
costs were divided into health-care visits and contacts,
hospitalizations and medications. The indirect costs com-
prised loss of productivity due to disability pensions and
absence from work due to sick leave. Only costs related to
asthma were included. Intangible costs, such as quality of
life and utilities, were not measured. The exchange rates at
the time for the study were close to USD 1 ¼ SEK 10.00, and
EUR 1 ¼ SEK 9.00.
Unit costs
Unit costs for health care resources were collected from the
county council in Norrbotten, Sweden, where all subjects
lived (Table 2). Drug prices were obtained from the Swedish
Pharmacopoeia.24 Only costs for drugs used due to asthma or
other airway complains related to or caused by asthma were
included. When calculating the value of the indirect costs,
the human capital approach was used.25 A full-time worker
was assumed to work 8 h a day, and the cost for absence
from work was calculated as the average pay in Sweden 1996
including pay-roll tax for men and women, SEK 1224 and SEK
935, respectively. Costs for disability pension were esti-
mated as absence from work every working day to an extent
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Table 2 Unit costs for health care contacts (SEK in
1996).
Contacts Unit
costs
Visit to primary care physician 1060
Visit to other primary care personnel 300
Visit to hospital-based physician 1060
Visit to other hospital-based personnel 300
Hospitalization 24 h, department of pulmonary
medicine
2540
Hospitalization 24 h, department of medicine 3290
Economic consequences of asthma among adults in Sweden 2265given by the grade of disability pension (100%, 75%, etc.).
A month was assumed to consist of 22 working days.
Analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) for Windows version
10.0. Chi-squared test was used for bi-variate comparisons
and one-way ANOVA for tests for trends. The 5% level
(po0.05) was considered statistically significant. As a
societal perspective was used in the analysis, both direct
and indirect costs were estimated. The resource use for
each subject with asthma was multiplied by the unit costs.
An average cost was calculated for the entire sample, and
the costs were also analyzed according to gender, age and
severity of asthma. A multiple logistic model was also
created with costs as a function of age, sex, smoking habits,
and severity of asthma (i.e. persistent or mild intermittent
asthma).
By multiplying the costs per patient with the estimated
number of asthmatics based on the prevalence of asthma,
the societal costs for all asthmatics between 25 and 56 years
in Sweden could be estimated. We used estimates of the
prevalence from northern Sweden and official population
data in order to estimate the total costs of asthma for the
Swedish society.
Results
Resource use
The number of consumed resource units increased by
severity of asthma and by age (Table 3). Subjects in the
oldest age group consumed considerably more resources
related to asthma. Of the study sample, 45% visited the
health-care sector during 1 year. In the oldest age group,
68% of the subjects visited a physician or other health-care
personnel at least once a year compared to 42% and 34% in
the younger age groups.
Total costs
The societal costs split into different cost items according to
age and disease severity are shown in Table 4. The annual
total societal costs were estimated at SEK 15 919 per patientwith asthma. The direct costs accounted for 31% and the
indirect for 69%. There was a substantial difference in total
costs among the different age groups and severity grades of
asthma. Subjects in the oldest age group were most
expensive (SEK 44 900) compared to SEK 3782 and SEK
3711 in the two younger age groups (p ¼ 0.009). In the
oldest age group, the indirect costs were higher than the
direct costs (75.7%), while in the two youngest, the direct
costs were higher than the indirect, 54.2% and 81.6%,
respectively. The total costs for subjects with persistent
asthma were estimated at SEK 27 628 compared to SEK 2222
for asthmatics with mild intermittent asthma (po0.001).
Direct costs
The average annual direct costs due to asthma were
estimated at SEK 4931. Subjects in the oldest age group
and those with persistent asthma had the highest direct
costs. The main disease-related cost driver among the direct
costs was medications, 56%, followed by outpatient care and
hospitalizations. Medicines were the main cost driver in all
age groups, and were more prominent in the two younger
age groups. The oldest age group had more visits to the
health-care sector and thus higher costs compared to the
asthmatics in the two younger age groups. To a large extent,
costs for hospitalizations accounted for the differences
observed among the direct costs, as all subjects who had
been hospitalized belonged to the oldest age group.
Indirect costs
The annual indirect costs were estimated at SEK 10 988 per
person with asthma. The main cost driver among the
indirect costs was loss of productivity due to disability
pension (76%). In the two younger age groups, all indirect
costs consisted of costs for absence from work, because no
asthmatics were early retired in these groups. Disability
pension accounted for 83% of the indirect costs in the oldest
age group.
Due to asthma, 10% had to stay at home from work at
some occasion during 1 year. The mean duration was 28
(2–105) days per episode. The average societal costs due to
loss of productivity amounted to SEK 2344 per subject.
Persons in the oldest age group had most days off work and
consequently the highest average costs. Only five persons in
the study sample were retired early due to asthma. The
annual average cost for the society due to loss of production
amounted to SEK 8644 per subject with asthma.
Multivariate relationships
A multiple logistic model was created with the probability of
costs as a function of age, sex, smoking habits, and severity
of asthma (i.e. persistent or mild intermittent asthma). Sex
and smoking habits were not significantly related to costs,
while age and severity of asthma were both strongly related
to costs (Table 5). When the analyses were performed
separately for mild intermittent asthma and persistent
asthma, respectively, the costs increased with increasing
age among those with persistent asthma, however, not
significantly so for mild intermittent asthma (Table 5).
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Table 3 Average annual resource consumption per patient with asthma according to age and severity of asthma.
Variables 25–26
(n ¼ 50)
40–41
(n ¼ 31)
55–56
(n ¼ 34)
Mild
intermittent
(n ¼ 53)
Persistent
(n ¼ 62)
Mean Difference (p-value) by
Age-group Severity
grade
Direct cost items
Hospitalizations
(number of days)
0 0 1.00 0 0.55 0.30 0.145 0.144
Outpatient care
(number of visits)
0.52 0.87 2.09 0.36 1.69 1.08 0.003 o0.001
Indirect cost items
Disability pension
(% of patients)
0 0 14.7 0 8.1 4.3
Absence from
work (number of
days)
2.10 0.48 5.79 1.70 3.66 2.76 0.113 0.428
Table 4 Average annual societal costs per patient with asthma according to agea and severity of asthmab (SEK in 1996).
25–26
(n ¼ 50)
40–41
(n ¼ 31)
55–56
(n ¼ 34)
Mild
intermittent
(n ¼ 53)
Persistent
(n ¼ 62)
Mean
Direct costs
Outpatient care 585 1013 2600 433 2034 1296
Hospitalization 0 0 2907 0 1594 859
Drugs 1467 2015 5396 540 4688 2776
Total direct costs 2052 3028 10 903 973 8316 4931
(SD) (3184.2) (4046.5) (14 518.1) (1875.1) (11 422.9) (9216.1)
% of group total 54.2 81.6 24.3 43.8 30.1 31.0
Indirect costs
Disability pensions 0 0 29 236 0 16 033 8644
Absence from work 1730 683 4761 1249 3279 2344
Total indirect costs 1730 683 33 997 1249 19 312 10 988
(SD) (9654.1) (3800.4) (81 583.8) (9094.6) (62 279.2) (46 850.3)
% of group total 45.8 18.4 75.7 56.2 69.9 69.0
Total costs 3782 3711 44 900 2222 27 628 15 919
(SD) (10 142.8) (6851.3) (86 396.5) (9203.1) (66 587.6) (50 724.2)
aTest for trend by age for both direct and indirect costs o0.001.
bChi-squared test by disease severity for both direct and indirect costs o0.001.
Table 5 Result of multiple regression analysis.
Variable b SE p-value
Constant 2.4933
Age 0.0236 0.0075 0.0017
Seriousness (mild ¼ 1, persistent ¼ 2) 0.8710 0.1963 o0.001
S.-A. Jansson et al.2266In both mild intermittent asthma (Figure 1) and persistent
asthma (Figure 2) the median costs were considerably lower
than the mean costs. The importance of increasing age forthe mean costs (more than median costs) for persistent
asthma is exemplified by Figure 2. In mild persistent asthma
both mean and median costs increases similarly with age
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Figure 1 Average annual societal costs per patient with mild
intermittent asthma according to age (SEK in 1996).
Persistent
0
5000
10000
15000
20000
25000
30000
20 30 40 50 60
Age (years) 
T
o
ta
l 
c
o
s
t 
(S
E
K
)
Mean
Median
25 percentile
75 percentile
Figure 2 Average annual societal costs per patient with
persistent asthma according to age (SEK in 1996).
Economic consequences of asthma among adults in Sweden 2267(Figure 1) though not significantly so. Figures 1 and 2 also
show that the mean value is higher than the 75th percentile.
This indicates that a very limited number of subjects in the
different age groups and different severity grades of asthma
consume the vast majority of resources. The cumulative
distribution of the total costs among subjects 25–26 years of
age, and subjects with persistent asthma, respectively is
shown in Figures 3 and 4. The total costs had a skewed
distribution, with most subjects being moderately costly and
a few very costly.Costs to society
As the number of subjects with asthma was estimated at
226 000 in the ages between 25 and 56 years in Sweden, the
annual total societal cost could be estimated at SEK 3.7
billion for all asthmatics in these age groups. The direct
costs would amount to SEK 1.1 billion and the indirect costs
would be SEK 2.6 billion. As the estimated total societalcosts do not include subjects younger than 25 years and
older than 56 years, the costs for asthma would probably be
approximately twice as high in the total population of
Sweden than the estimated costs in our study.Discussion
Knowledge about how much different diseases affect the
society in terms of costs is necessary in order to plan and
implement different kind of health-policy interventions. It is
also important to know what kind of costs different diseases
impose on the society. Asthma is a common disease
worldwide and also in Sweden, and there has been a
considerable increase of the prevalence during the past five
decades.1,2 Studies about costs of asthma have been
performed in many countries,9–15 but still there is a lack
of data about costs based on studies of the general
population.
The best method to measure the real costs is by
prospective collection of real expenses and consumption of
health care resources within a cohort of subjects with
asthma. The cohort must be representative for the general
population regarding the distribution of age, gender and
severity of the disease. In our study, we examined by using
interview the societal costs of a representative cohort of
adult asthmatics in northern Sweden retrospectively cover-
ing a 1-year period. The costs were analyzed at an individual
level, and we examined also the relationship between age
and costs, and between severity of asthma and costs. An
aggregation of the costs to the level of the Swedish society
was then made based on the estimated prevalence of the
disease assuming that the prevalence of asthma in Norrbot-
ten is similar to Sweden as a whole.
We found that asthma is a costly disease for the Swedish
society. The major findings included that the annual total
societal costs amounted to SEK 15 919 (USD 1592; Euro 1768)
per patient with asthma of which direct costs accounted for
31%. There was a substantial difference in costs by age and
severity of disease, while other possible determinants as sex
or smoking habits was not significantly related to costs. The
costs in the oldest age group were considerably higher
compared with the asthmatics in the two younger age
groups. Subjects with persistent asthma had ten times
higher costs compared to asthmatics with mild intermittent
asthma. Mean costs were considerably higher than median
costs in both mild intermittent and persistent asthma. In
both severity grades, less than 25% of the asthmatics had
considerably higher costs compared with the others.
The key cost driver among the direct costs was drugs,
both in the different age groups and also among the
different severity grades of asthma. Data available from
other countries show a similar distribution among the direct
costs. Studies performed in the Netherlands, the United
States and France have shown that medications was the key
cost driver among the direct costs.9,12,13 Disability pension
was the key cost driver among the indirect costs, but only in
the oldest age group and in persistent asthma. Most studies
have shown a similar distribution also among the indirect
costs, and our results correspond well with a study
performed in the United States, where the costs of disability
pension accounted to 61% of the indirect costs.12 However,
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Figure 3 The cumulative distribution of total costs among subjects 25–26 years of age.
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Figure 4 The cumulative distribution of total costs among subjects with persistent asthma.
S.-A. Jansson et al.2268one study in Germany has shown that costs for sick leave due
to asthma were higher than costs for disability pension.13 In
that study, also children were included in contrast to our and
most other studies, thus, the impact of disability pension is
smaller in the German study.
Assuming that the selection is representative for the
Swedish population, the prevalence would be 6–7% and the
asthmatics in Sweden would amount to about 226 000 in the
ages between 25 and 56 years. The total costs for the society
could be estimated at about SEK 3.7 billion for all asthmatics
in these ages. The direct costs would amount to SEK 1.1
billion and the indirect costs would be SEK 2.6 billion. The
total costs of asthma for Sweden as a whole would thus
presumably be estimated at approximately twice as high.
However, the prevalence in northern Sweden may besomewhat higher than in other parts of Sweden,6 why the
estimated costs for Sweden as a whole may be slightly over-
estimated. On the other hand, the selection procedure may
have resulted in a loss of subjects with mild intermittent
asthma.
There has been an increasing interest in the burden of
asthma worldwide, as evidenced by a number of cost-of-
illness studies.8 These studies are difficult to compare
because of differences in study designs, definitions of costs
and different time periods. Most of them have been register-
based studies.9–15 Studies in United States, United Kingdom,
Australia and the Netherlands have shown an average annual
societal burden ranging from USD 326 to USD 1315 per
subject.8 In a study performed in the USA, the annual total
costs per subject were estimated at 4912 US dollars, the
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Economic consequences of asthma among adults in Sweden 2269direct costs accounted for 65% of the total costs.12 The main
cost driver among the direct costs was asthma-medicines
(50%). A study performed in Germany found the indirect
costs to be 75% of the total costs.13 Several studies have also
shown that costs for asthma are strongly correlated to
disease severity.12,14,15
A previously published Swedish study based on register
data26 estimated the societal costs of asthma in Sweden to
SEK 3 billion, the direct costs accounting to 35% of the total
costs. The distribution of the total costs into direct and
indirect costs corresponded well with our study, although
our study resulted in considerably higher costs of asthma for
the society. However, it is difficult to compare results from
different studies with different study designs. Our study was
performed later, and one explanation of the higher costs in
our study could be that the prevalence may have increased,
but this is probably not the main explanation. Another
contributing explanation could be that the costs of drugs
have increased steadily. As mentioned, there may also exist
a difference in prevalence in the northern part of Sweden
compared to the central and southern part. However, our
study was based on samples of the general population, while
the referred study26 was based on register data. An
important reason for the higher costs in our study compared
to the previously performed Swedish study could be
explained by under-diagnosis, which cannot be corrected
for in register studies. Further, costs for health care
provided by private physicians and clinics were not included
in the register-based study.
Comparable data from Scandinavian countries are sparse.
Two published Danish studies, both performed in 1995,
based on 115 and 190 asthmatics, respectively, yielded costs
transformed to the population size of Sweden of 3–4 and 6–7
billion SEK, respectively.27,28 The data in both these studies
were collected by interviews at pharmacies.
There are both advantages and disadvantages when
comparing population-based studies using interviews with
studies based on register data. The data collected in
individual interviews are more detailed compared with data
from register studies. The risk of selection bias and under-
estimation of costs is also reduced because it is possible to
‘‘coach’’ the patient. However, interview-based studies also
have limitations. There is a risk of recall bias when subjects
are asked questions from a period lasting for 1 year. Another
disadvantage in using individual interviews is the risk that
the study could be based on too few patients due to high
costs when performing such studies resulting in wide
confidence intervals. The questionnaire must be standar-
dized, which means that the questions must be formulated
in exactly the same way in all settings. Further, the
questionnaire must also contain clear questions that are
easy to understand in order to minimize the risk of errors.
Aiming to eliminate inter-observer bias, all interviews in our
study were carried out by one person (SAJ).
Several studies have shown that in self-reports, it may be
difficult for patients to remember all events that have
occurred during a 1-year period.29–31 This may result in an
underestimation of the costs. In this study we tried to
minimize the risk of recall bias in several ways when the
interviews took place. When asking questions about visits to
the health care sector and hospitalizations during the last
year, we also asked when and where the patients had visitedthe health care sector or had been hospitalized. Regarding
utilization of medications, the patients were asked to bring
their medications to the phone in order to get the correct
name, dose and strength.
The data in this study can be considered as valid, as a
random sample from a large-scale population study was
used. Thus the study sample is representative for adult
asthmatics in the general population of northern Sweden.
The high participation rate in our study (89%) and also in the
population study from which the asthmatics were derived
from21 is also an evidence of this. Further, questionnaire
reported asthma has been found valid with a high
specificity,32 particularly in studies in Sweden.33,34 When
estimating the costs of asthma for Sweden as a whole, we
have assumed that there are no major differences between
asthmatics in northern Sweden compared to asthmatics in
central and southern Sweden in terms of prevalence,
treatment patterns and early retirement due to asthma.
In conclusion, we found that asthma is a costly disease for
the society. We also found that the costs are strongly
correlated to age and severity of asthma among adult
asthmatics. The costs for subjects with persistent asthma
were more than ten times greater compared to the costs for
subjects with mild intermittent asthma. Subjects in the
oldest age group had more than ten times higher costs
compared to subjects in the younger age groups. The total
costs for asthma in Sweden could be estimated at SEK 3.7
billion in the ages between 25 and 56 years, with the direct
costs accounting for 31% of the total.Acknowledgements
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